

1
2 **Examining the incidence of DELIRIUM in Canadian Cardiac Surgery patients: a protocol for the**
3 **DELIRIUM-CS Canada cross-sectional study.**
4
5

6
7 The DELIRIUM-CS Investigators* on behalf of The Canadian Cardiovascular Critical Care (CANCARE)
8
9 Society Investigator Group and the Canadian Critical Care Trials Group
10
11

12
13
14 *Corresponding author:

15
16
17 R.C. Arora MD PhD FRCSC
18 CR3012-369 Tache Ave.
19 St. Boniface Hospital
20 Winnipeg, Manitoba
21 R2H 2A6
22 rakeshcarora@gmail.com
23
24
25
26
27
28

29 Word Count: 3516 (including references and table & figure legends)
30
31
32
33

34 ***DELIRIUM-CS Investigators:** Alan Sobey (Edmonton, AB), Barry Kushner, Philippe Couillard, Andre
35 Ferland (Calgary, AB); **Rakesh C. Arora (Lead Author)**, Kelsey Uminski, Navdeep Tangri, Hilary Grocott,
36 Brett Hiebert (Winnipeg, MB); Dave Nagpal (London, ON); Alison Fox-Robichaud (Hamilton, ON), Lisa
37 Hutchinson (Newmarket, ON); George Djainai, Angela Jerath (Toronto, ON), Bernard McDonald
38 (Ottawa, ON); Yoanna Skrobik (Montreal, QC); Sheldon Magder (Montreal, QC); Yoan Lamarche Marie-
39 Claude Cote, Andre Denault (Montreal, QC); Ansar Hassan (Saint John, NB); Jean-Francois Legare
40
41
42
43
44
45
46
47
48
49 (Halifax, NS).
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background: As a recognized complication of cardiac surgery, increasing attention has been paid to the negative effect of delirium on post-operative outcomes. Despite this, little is still known about the true incidence of delirium following cardiac surgery, with published rates ranging widely from 3% - 78%.

This study aims to use validated and easily implementable bedside tools to determine the incidence of delirium in a contemporary cardiac surgery population.

Methods: The DELIRIUM-CS Canada study is a multicenter cross-sectional cohort study. Over a three month period, all patients undergoing major cardiac surgical procedures at each of the participating centers will be screened for post-operative delirium using either the Intensive Care Delirium Screening Checklist or Confusion Assessment Method for the Intensive Care Unit tool. Delirium screening will be conducted for either up to 7 days following their date of surgery or up until their date of initial discharge from the intensive care unit, whichever comes first. In addition to reporting an overall rate of delirium, unadjusted and adjusted incidence rates of delirium will be reported by institution and for the entire cohort. Risk-adjustment will be performed using multivariate regression modeling techniques.

Interpretation: The results of this study will provide valuable insight into the true burden of delirium among patients having undergone a major cardiac surgical procedure in the current era. This is the first step in creating a multifaceted delirium prevention/treatment clinical pathway for the cardiac surgery patient.

Trial Registration: ClinicalTrials.gov register Number: NCT02206880

Keywords: delirium; cardiac surgery; prevention; screening tool; confusion assessment method

Introduction

Delirium is an acute confusional state characterized by fluctuating mental status, inattention, and either disorganized thinking or altered level of consciousness.¹⁻⁵ It has long been recognized as a complication of cardiac surgery, a condition more likely to be experienced among older adult patients and those with greater comorbid disease burden.⁶⁻⁸ In recent years, increasing attention has been paid to the negative effect of delirium on health care costs and post-operative outcomes, including long-term survival, freedom from hospital readmission and reduced cognitive and functional recovery.⁹⁻¹⁸

Despite this, little is known about the true burden of delirium among patients having undergone a cardiac surgical procedure. Reported rates of delirium range widely, with rates as low as 3% but as high as 78% depending on the type of cardiac surgery, the method of detection, and the definition of delirium being used.^{7,9-14} Despite its strong association with adverse post-operative events, delirium is an often under-recognized source of end-organ dysfunction. In the absence of an active screening program, delirium can go undiagnosed in greater than 70% of cases.^{15,16}

Over the past two decades, the risk profile of patients undergoing cardiac surgery has changed. Increasingly, cardiac surgical procedures are being performed on older patients with recent coronary syndromes, higher New York Heart Association classifications, lower left ventricular ejection fractions and cardiogenic shock, all of which are associated with increased rates of postoperative delirium.^{6,14}

While the precise incidence of delirium in the current era of cardiac surgery is unclear, it is likely that it will continue to increase due to the aging demographic of the “typical” cardiac surgery patient.

Therefore, quantifying the magnitude of delirium in a large contemporary sample of the population is the first critical step in addressing the prevention and treatment of this important, common and yet life-threatening complication.

1 The CANadian CARdiovascular critical carE (CANCARE) Society (www.cancaresociety.com), founded in
2
3
4 2009, is a multidisciplinary group created to improve the quality of care of critically ill cardiovascular
5
6 patients using multidisciplinary expertise in a cooperative model. The founding committee has
7
8 identified postoperative delirium (PoD) in the cardiac patient as a national priority for investigation and
9
10 initiated planning of the DELIRIUM-CS Canada Study in the summer of 2011. Through a network
11
12 created within the CANCARE society, the aims of this study are threefold: (1) To identify the true
13
14 burden of delirium using a “standardized” definition among patients having undergone a cardiac
15
16 surgical procedure in 11 centers across Canada; (2) To determine the impact on healthcare utilization
17
18 (as determined by intensive care unit (ICU) and hospital length of stay (LOS)) and postoperative
19
20 mortality; and (3) To determine modifiable and non-modifiable risk factors for the occurrence of
21
22 delirium in a large, multicentre cohort of contemporary cardiac surgery patients. We hypothesize that
23
24 delirium, identified through a systematic and standardized postoperative screening protocol is a highly
25
26 prevalent, though variable, condition following cardiac surgery. Secondly, we hypothesize that the
27
28 occurrence of PoD is associated with prolonged hospital LOS and other negative outcomes.
29
30
31
32
33
34
35
36
37
38

39 **Methods and Analysis**

40
41 The DELIRIUM-CS Canada study is a multicentre cross-sectional cohort study designed to determine the
42
43 incidence of delirium across 11 cardiac surgery centers in Canada using a standardized delirium
44
45 screening methodology. The trial has been registered on National Institutes of Health ClinicalTrials.gov
46
47 (NCT02206880). This study has been approved by the University of Manitoba Research Ethics Board
48
49 (REB) as well as the REB at each of the participating centers. The study will be conducted in accordance
50
51 with the International Conference on Harmonisation and Good Clinical Practice principles.
52
53
54
55
56
57
58
59
60

Setting

The DELIRIUM-CS study will be conducted in 11 centers across Canada: Edmonton, AB; Calgary AB; Winnipeg MB; Hamilton ON, Newmarket ON, Toronto ON, Ottawa ON, Montreal (two sites) QC, Saint John NB and Halifax NS. Over a three-month period, all patients undergoing cardiac surgical procedures at each of the participating centers will be screened for post-operative delirium.

Each site will have identified personnel for the collection and entry of data for the study.

The Site Principal Investigator (PI) will be responsible for the conduct of the study and ethics approval at that site. Site communications and study documents will be sent to hospital PIs in addition to any nominated research personnel associated with that site.

Participant Selection

Inclusion Criteria

All patients undergoing cardiac surgery who are admitted to an ICU or cardiac surgery recovery unit (CSRU) following their procedure. Patients will not be excluded on the basis of urgency or procedure type.

Exclusion Criteria

Patients in whom delirium cannot be reliably tested (e.g., previous debilitating stroke, cerebral palsy, previous history dementia, recent history of a psychotic disorder, severe hearing disabilities or inability to understand English or French, active seizure disorder or Child-Pugh class B or C cirrhosis) or with known preoperative delirium. Cardiac surgery procedures that do not require an admission to an ICU (i.e. pacemaker insertion or sternal debridement admitted to the ward) will be excluded.

Screening Tools

1
2 Each centre will be allowed to employ either the Intensive Care Delirium Screen Checklist (ICDSC)¹ or
3
4 the Confusion Assessment Method – Intensive Care Unit (CAM-ICU)³ tool (Table 1) to detect delirium.
5
6 Similarly, either the Riker Sedation Agitation Scale (SAS)²⁷ or the Richmond Agitation-Sedation Scale
7
8 (RASS)²⁸ will be used to determine levels of sedation and agitation (Table 2). A Sedation/Agitation
9
10 score will need to be paired with each delirium screening assessment. It is up to the centre to decide
11
12 which tool they wish to use. The Richmond Agitation-Sedation Scale and Sedation-Agitation Scale are
13
14 the most valid and reliable sedation assessment tools for measuring quality and depth of sedation in
15
16 adult ICU patients.²⁹ Simultaneous sedation assessments are important to differentiate delirium
17
18 assessments confounded by sedation level with delirium independent of concomitant sedation³⁰.
19
20 A delirium screen with either the ICDSC or CAM-ICU should be performed at least every 12 hours (i.e.
21
22 once per shift, with the first assessment in the morning and a second assessment with the beginning of
23
24 the evening shift) and should be performed concomitantly with either the SAS or RASS assessment.
25
26
27
28
29
30
31

32 **Data Sources and Collection**

33
34
35 Data will be extracted prospectively from patient clinical records at each participating site for the
36
37 purposes of completing their respective cardiac surgery database/registry. Delirium screening will be
38
39 conducted by trained bedside personnel on all patients admitted post-operatively to the ICU or CSRU,
40
41 starting on the first postoperative day. Delirium screening will be conducted for 7 days following their
42
43 date of surgery (i.e. postoperative day #1) or until their date of initial discharge from the intensive care
44
45 unit, whichever comes first. Data relating to the delirium and sedation scales will be captured in the
46
47 accompanying CRF.
48
49
50
51

52
53 In addition to administering the delirium and sedation/agitation screening tools, data regarding
54
55 baseline demographic and clinical characteristics as well as data regarding the procedure performed
56
57 (see Case Report Form (CRF)). Baseline data collected for each patient will include: date of surgery,
58
59
60

1 surgical procedure, procedure urgency, sex, age, ICU admission date and time, co-morbidities
2
3
4 (hypertension, diabetes, hyperlipidemia, smoking history, chronic obstructive pulmonary disease,
5
6 peripheral vascular disease, previous cerebrovascular accident), EUROScore II, and length of stay in
7
8 both ICU and hospital. Delirium episode data will include each of the CAM-ICU/ICDSC and RASS/SAS
9
10 scores, the attending physician's diagnosis of delirium, and whether or not the patient is receiving
11
12 pharmacologic therapy for delirium episode. As this is a cross-sectional study using data collected as
13
14 part of routine clinical practice, no safety monitoring will be undertaken.
15
16
17
18
19
20

21 **Statistical Analysis**

22 **Measured Outcome**

23
24
25
26
27 Patients will be considered as having had post-operative delirium if the results of at least one of the
28
29 screening tests administered yielded a positive finding of delirium more than 6 hours after anesthesia
30
31 emergence (defined as stopping sedation in either the operating room or in the postoperative
32
33 intensive care unit). In addition to reporting an overall rate of delirium, unadjusted and adjusted
34
35 incidence rates of delirium will be reported by institution. Crude rates for delirium will be reported
36
37 with the potential of generating a risk model using multivariate regression modeling techniques to
38
39 determine predictors of PoD in patients following cardiac surgery.
40
41
42
43

44 **Sample Size**

45
46
47 As the primary goal of this study is to determine the incidence of postoperative delirium, there is no
48
49 required sample size that has been calculated for this study. However, based on our¹⁹ and other recent
50
51 analyses^{13,17,18}, the average surgical volumes of each of the centers involved, we expect approximately
52
53 150-400 patients per site to be enrolled for the three month evaluation period.
54
55
56
57
58
59
60

Data Management

The data management and analysis will be undertaken by the St. Boniface Hospital/I.H. Asper Clinical Research Institute. The principal means of data collection and data processing will be via electronic data entry at each site. Data will be exported to the St. Boniface Hospital/I.H. Asper Clinical Research Institute stripped of any patient identifiers. Each patient will be given a site and an anonymous unique study number. No site monitoring will be performed. De-identified data will be entered by each participating site into an electronic CRF. Master log sheets with identifying details will remain confidential and will be stored securely at participating sites to enable data queries to be addressed if required. Master log sheets or any other identifying information will not be submitted to the study office at the St. Boniface Hospital. All data collected by the study will be kept for a minimum of 7 years, or as otherwise required by regulatory authorities. The St. Boniface Hospital/I.H. Asper Clinical Research Institute will be the data custodians and all electronic data will be stored and backed up on password-protected servers. All paper data will be archived and stored in a secure facility at each participating centre. Data entered by each site will be password-protected and the ability to access or change data prior to locking of the database will be restricted to that site and staff managing data at the St. Boniface Hospital. Once initial data collection has been completed, missing data and implausible values will be identified using predetermined objective criteria, and queries resolved through direct communication with sites if required. This data cleaning process will be overseen by the DELIRIUM-CS Canada management committee.

Trial Monitoring and Oversight

The DELIRIUM-CS Canada management committee is responsible for all aspects of study design, management, analysis and publication of results. In addition, the management committee is responsible for ensuring that the study meets the proposed milestones and deadlines.

Regulatory Requirements

This study is low-risk and will not affect patient management in any way. Delirium screening is considered an accreditation standard in Canadian ICUs and routinely performed as part of daily assessments.³¹ Finally, given that data will be collected at participating sites from de-identified medical records, procedures will be put in place to protect patient privacy. Information identifying individual patients will be kept confidential at each site and will be stored securely. This will allow data queries to be addressed, which is essential to ensure data integrity, but this information will not be sent to the St. Boniface Hospital/I.H. Asper Clinical Research Institute. De-identified data sent to the St. Boniface Hospital/I.H. Asper Clinical Research Institute will be stored securely in locked files or password-protected electronic files. Data from individual patients will be combined and will not be presented in a manner that would allow the identification of any individual patient.

Participating ICUs are involved voluntarily, and there is implied consent from participating units, indicated by their agreement to participate and a memorandum of understanding if necessary will be signed between the participating ICUs and the St. Boniface Hospital/I.H. Asper Clinical Research Institute.

Interpretation

1
2 Herein we described our multicenter cross-sectional study, which aims to determine the incidence of
3
4 delirium across 11 cardiac surgery centers in Canada using a standardized delirium screening
5
6 methodology. This study will be the first to report on incidence rates of new delirium following cardiac
7
8 surgery across multiple centers employing standardized screening methodologies. The advantages of
9
10 this employed approach is that data from high volumes centre, both academic and community site will
11
12 be collecting all consecutive patients in the same time period. Therefore, quantifying the magnitude of
13
14 delirium in a large contemporary sample of the population is the first critical step in addressing the
15
16 prevention and treatment of this important, common and yet life-threatening complication. Secondly,
17
18 the study will provide a pragmatic rates delirium detection using bedside personnel. The advantage of
19
20 this approach is that it will provide valuable insight into the “real-world” detectable burden of delirium
21
22 among patients having undergone a cardiac surgical procedure in the current era. While it would be
23
24 ideal to have reference standard of a trained research personnel or other reference standard, it would
25
26 not have been possible for this study. This may therefore result in under-reporting of the actual
27
28 delirium rates. Nonetheless, each site will have undergone extensive training of bedside personnel
29
30 using implementation strategies that have been shown to be effective in delirium detection.^{19–26}
31
32 Ultimately it is anticipated that this initiative will be an important first step in creating a multifaceted
33
34 delirium prevention/treatment clinical pathway for the cardiac surgery patient.
35
36
37
38
39
40
41
42
43
44
45
46

47 **Limitations**

48
49 Given the observational nature of the study, efforts have been made to address potential sources of
50
51 bias in our study. To mitigate the effects of participant selection bias in our study, patients will not be
52
53 excluded on the basis of urgency or procedure type. At the institution-level, we will compare incidence
54
55 rates of post-operative delirium between both academic and non-academic participating sites. A
56
57
58
59
60

1 potential limitation that must be considered how a handle data generated from a centre(s) with a low
2 screening rate (and perhaps too high). Upon completion of data collection for all reporting centres, we
3
4
5
6 will need to consider a threshold below which the centre's data will not be included. This may provide
7
8
9 the opportunity to make novel contribution in that we may able to “test” approaches to
10
11
12 implementation of screening tools in each institution. Indeed, it may be that some centres may be
13
14
15 better or have improvements over the 3 months of collection. We will consider the use of a sensitivity
16
17
18 analysis to examine how predictors change with the inclusion and exclusion of certain sites with either
19
20
21 high or low screening rates. The variability in the reporting, in of itself, may be quite revealing. This
22
23
24 may offer opportunity to look at barriers to implementation on a more qualitative manner and open
25
26
27 the door to mixed methods analysis. Although screening for delirium is an accreditation standard in
28
29
30 Canadian ICUs, compliance rates with the use of the screening tools will be assessed, and potential
31
32
33 barriers to implementation of the tools identified.

32 **Knowledge Translation**

34 We will use the “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE)
35
36
37 Statement that are guidelines for reporting observational studies.²⁶ Data collected in the study will be
38
39
40 presented at the Annual Scientific Meeting of the CANSOC Society Investigator Group, Scientific
41
42
43 Meetings of the Canadian Critical Care Trials Group, and other forums as deemed appropriate. Data
44
45
46 will subsequently be used for scientific publications in academic journals.

47 **Conclusions**

49 In summary, we describe the protocol for the DELIRIUM-CS Canada study. Our study proposes to
50
51
52 determine the true incidence of delirium among Canadian cardiac surgery patients using a
53
54
55 standardized delirium screening methodology, as a first step in creating a national
56
57
58 prevention/treatment clinical pathway for the cardiac surgery patient.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing Interests

The authors declare that they have no competing interests.

Contributors

This study will be published under the authorship of the CANCARE Society Investigator Group investigators with the writing committee listed as primary authors. All participating investigators will be listed under such group identifier in an appendix.

Funding

The study is funded by a Meeting and Planning Grant from the Canadian Institutes of Health Research (KPE-126811). The St. Boniface Hospital/I.H. Asper Clinical Research Institute will fund data management, operations and analysis. No site payments are available at the time of writing but funding will be sought.

References

1. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med 2001 May;27(5):859-864.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Jr, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. *JAMA* 2004 Apr 14;291(14):1753-1762.
3. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med* 2001 Jul;29(7):1370-1379.
4. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegel AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med* 1990 Dec 15;113(12):941-948.
5. Inouye SK, Bogardus ST, Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med* 1999 Mar 4;340(9):669-676.
6. Kornfeld DS, Heller SS, Frank KA, Moskowitz R. Personality and psychological factors in postcardiotomy delirium. *Arch Gen Psychiatry* 1974 Aug;31(2):249-253.
7. van der Mast RC, Roest FH. Delirium after cardiac surgery: a critical review. *J Psychosom Res* 1996 Jul;41(1):13-30.
8. Gokgoz L, Gunaydin S, Sinci V, Unlu M, Boratav C, Babacan A, et al. Psychiatric complications of cardiac surgery postoperative delirium syndrome. *Scand Cardiovasc J* 1997;31(4):217-222.

- 1
2 9. Rudolph JL, Jones RN, Grande LJ, Milberg WP, King EG, Lipsitz LA, et al. Impaired executive
3
4 function is associated with delirium after coronary artery bypass graft surgery. *J Am Geriatr Soc*
5
6 2006 Jun;54(6):937-941.
7
8
- 9
10 10. Rudolph JL, Inouye SK, Jones RN, Yang FM, Fong TG, Levkoff SE, et al. Delirium: an independent
11
12 predictor of functional decline after cardiac surgery. *J Am Geriatr Soc* 2010 Apr;58(4):643-649.
13
14
- 15
16 11. Martin BJ, Buth KJ, Arora RC, Baskett RJ. Delirium: a cause for concern beyond the immediate
17
18 postoperative period. *Ann Thorac Surg* 2012 Apr;93(4):1114-1120.
19
20
- 21
22 12. Loponen P, Luther M, Wistbacka JO, Nissinen J, Sintonen H, Huhtala H, et al. Postoperative
23
24 delirium and health related quality of life after coronary artery bypass grafting. *Scand Cardiovasc*
25
26 *J* 2008 Oct;42(5):337-344.
27
28
- 29
30 13. Gottesman RF, Grega MA, Bailey MM, Pham LD, Zeger SL, Baumgartner WA, et al. Delirium after
31
32 coronary artery bypass graft surgery and late mortality. *Ann Neurol* 2010 Mar;67(3):338-344.
33
34
- 35
36 14. Koster S, Hensens AG, Schuurmans MJ, van der Palen J. Consequences of delirium after cardiac
37
38 operations. *Ann Thorac Surg* 2012 Mar;93(3):705-711.
39
40
- 41
42 15. Koster S, Hensens AG, van der Palen J. The long-term cognitive and functional outcomes of
43
44 postoperative delirium after cardiac surgery. *Ann Thorac Surg* 2009 May;87(5):1469-1474.
45
46
- 47
48 16. Saczynski JS, Marcantonio ER, Quach L, Fong TG, Gross A, Inouye SK, et al. Cognitive trajectories
49
50 after postoperative delirium. *N Engl J Med* 2012 Jul 5;367(1):30-39.
51
52
53
54
55
56
57
58
59
60

- 1
2 17. van Dijk D, Keizer AM, Diephuis JC, Durand C, Vos LJ, Hijman R. Neurocognitive dysfunction after
3
4 coronary artery bypass surgery: a systematic review. *J Thorac Cardiovasc Surg* 2000
5
6 Oct;120(4):632-639.
7
8
- 9
10 18. Inouye SK. Delirium in older persons. *N Engl J Med* 2006 Mar 16;354(11):1157-1165.
11
12
- 13
14 19. Arenson BG, MacDonald LA, Grocott HP, Hiebert BM, Arora RC. Effect of intensive care unit
15
16 environment on in-hospital delirium after cardiac surgery. *J Thorac Cardiovasc Surg* 2013
17
18 Jul;146(1):172-178.
19
20
- 21
22 20. Martin BJ, Buth KJ, Arora RC, Baskett RJ. Delirium as a predictor of sepsis in post-coronary artery
23
24 bypass grafting patients: a retrospective cohort study. *Crit Care* 2010;14(5):R171.
25
26
27
- 28
29 21. Sockalingam S, Parekh N, Bogoch II, Sun J, Mahtani R, Beach C, et al. Delirium in the
30
31 postoperative cardiac patient: a review. *J Card Surg* 2005 Nov-Dec;20(6):560-567.
32
33
34
- 35
36 22. Rudolph JL, Jones RN, Levkoff SE, Rockett C, Inouye SK, Sellke FW, et al. Derivation and validation
37
38 of a preoperative prediction rule for delirium after cardiac surgery. *Circulation* 2009 Jan
39
40 20;119(2):229-236.
41
42
43
- 44
45 23. Koster S, Hensens AG, Schuurmans MJ, van der Palen J. Prediction of delirium after cardiac
46
47 surgery and the use of a risk checklist. *Eur J Cardiovasc Nurs* 2013 Jun;12(3):284-292.
48
49
- 50
51 24. Pisani MA, Redlich C, McNicoll L, Ely EW, Inouye SK. Underrecognition of preexisting cognitive
52
53 impairment by physicians in older ICU patients. *Chest* 2003 Dec;124(6):2267-2274.
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Katznelson R, Djaiani G, Tait G, Wasowicz M, Sutherland AM, Styra R, et al. Hospital administrative database underestimates delirium rate after cardiac surgery. *Can J Anaesth* 2010 Oct;57(10):898-902.
 26. Vandembroucke JP, von Elm E, Altman DG, Gotsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014 Dec;12(12):1500-1524.
 27. Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. *Crit Care Med* 1999 Jul;27(7):1325-1329.
 28. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med* 2002 Nov 15;166(10):1338-1344.
 29. Khan BA, Guzman O, Campbell NL, Walroth T, Tricker J, Hui SL, et al. Comparison and agreement between the Richmond Agitation-Sedation Scale and the Riker Sedation-Agitation Scale in evaluating patients' eligibility for delirium assessment in the ICU. *Chest* 2012 Jul;142(1):48-54.
 30. Can delirium Assessments Be Accurately Labelled (CABAL) Investigators group, Devlin JW, Fraser GL, Joffe AM, Riker RR, Skrobik Y. The accurate recognition of delirium in the ICU: the emperor's new clothes? *Intensive Care Med* 2013 Dec;39(12):2196-2199.
 31. Accreditation Canada. 2013. [<http://www.accreditation.ca/en/>]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table Legends

Table 1- Delirium Screening Equivalency Table

Table 2- Sedation and Agitation Scales

Appendix

Case Report Form

Delirium Assessment Form

Confidential

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 – Delirium Screening Equivalency Table

	Intensive Care Delirium Screen Checklist (ICDSC) ¹	Confusion Assessment Method – Intensive Care Unit (CAM-ICU) ^{2,3}
Onset	Single score of ≥ 4	Single CAM-ICU+ screen
Termination	Three (3) consecutive negative (i.e. 36 hours) ICDSC assessments	Three (3) consecutive negative (i.e. 36 hours) CAM-ICU assessments

Comment [dmc1]: Is there any room for attending clinician to diagnose delirium despite negative screening tool? Should there be?

Comment [A2]: Agree with this definition

Table 2 - Sedation and Agitation Scales

Riker Sedation Agitation Scale (SAS)		Richmond Agitation-Sedation Scale (RASS)	
7 - Dangerous Agitation	Pulling at ET tube, trying to remove catheters, climbing over bedrail, striking at staff, thrashing side-to-side	+4 - Combative	Overtly combative, violent, immediate danger to staff
6 - Very Agitated	Requiring restraint and frequent verbal reminding of limits, biting ETT	+3 - Very Agitated	Pulls or removes tube(s) or catheter(s); aggressive
5 - Agitated	Anxious or physically agitated, calms to verbal instructions	+2 - Agitated	Frequent non-purposeful movement, fights ventilator
4 - Calm and cooperative	Calm, easily arousable, follows commands	+1 - Restless	Anxious but movements not aggressive vigorous
3 - Sedated	Difficult to arouse but awakens to verbal stimuli or gentle shaking, follows simple commands but drifts off again	0 - Alert and calm	
2 - Very Sedated	Arouses to physical stimuli but does not communicate or follow commands, may move spontaneously	-1 - Drowsy	Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (>10 seconds)
1 - Unarousable	Minimal or no response to noxious stimuli, does not communicate or follow commands	-2 - Light Sedation	Briefly awakens with eye contact to voice (<10 seconds)
		-3 - Moderate Sedation	Movement or eye opening to voice (but no eye contact)
		-4 - Deep Sedation	No response to voice, but movement or eye opening to physical stimulation
		-5	No response to voice or physical stimulation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CASE REPORT FORM

Patient initials _____

Date of birth ____/____/____

Date of surgery ____/____/____

Procedure CABG
 Valve
 CABG+valve
 Other

Sex Male Female

Hypertension Yes No

Dyslipidemia Yes No

Diabetes Yes No

Smoking History Yes No

COPD Yes No

Renal insufficiency Yes No

PVD Yes No

CVD Yes No

Confidential

Comment [RA1]: What's your definition for renal insufficiency?? e.g. all patients with GFR <60 mL/min/1.73 m² for ≥3 months

Comment [AYD2]: Add a list of abbreviations at the beginning

Delirium Assessment

	Shift 1 (i.e. 0700-1500hrs)		Shift 2 (i.e. 1500hrs – 2300hrs)		Shift 3 (i.e. 2300hrs – 0700hrs)	
	CAM-ICU/ICDSC	SAS/RASS	CAM-ICU/ICDSC	SAS/RASS	CAM-ICU/ICDSC	SAS/RASS
Day 1						
Day 2						
Day 3						
Day 4						
Day 5						
Day 6						
Day 7						

Confidential

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.